SecBot SecBot

SBFM

Sunshine Biopharma Inc.
Nasdaq· Pharmaceutical Preparations· Inc. CO· CIK 0001402328 Biotech & Drug Discovery
$2.96 +0.31 (+11.70%)
Oct 27 4:00 PM ET · prev $2.65
Market cap
$2.3M
Nano cap
Median target
$1,120.00
+37738% · range $1,120.00–1,120.00
Next earnings
Nov 11
in 15 days · EPS est. −$3.40
1 year
−99.2%
from $368.00 · Oct 28
30 days
−81.9%
from $16.36
52-week range
$2.65–368.00
−99% from high · low Oct 26
Avg volume 20D
856.5K
Oct 7 spike 8.90M
Short interest
840.9K
≈5.5% of shares · +539.6%
Days to cover
1.0
at average volume
Insider net
$0
no open-market trades · 12 mo
Filing reports
11
analyzed by SecBot
SecBot read BEARISH 10 reports · 90 days
Balance 6 bearish · 0 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 9/10 ·Next Earnings date, Nov 11, 2026
Strongest BEARISH Sunshine Biopharma priced a best-efforts offering of up to 10,509,082 Common Units at $0.55/unit, each…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • EstimatesRISING

    Current-quarter EPS estimate −$4.000 → −$3.400 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersBUILDING

    Short interest +539.6% to 840.9K shares. 1.0 days to cover, ≈5.5% of shares.

  • TrendDOWNTREND

    81% below its 50-day average. New closing low $2.65 on Oct 26.

Who's buying

13F
Top holderSharesValue
JANE STREET GROUP, LLC14,974$31.4K
MORGAN STANLEY385$808.00
NATIONAL BANK OF CANADA /FI/5$10.00
OSAIC HOLDINGS, INC.2$4.00
Farther Finance Advisors, LLC1$2.00
TD Waterhouse Canada Inc.1$2.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Oct 2025
12-month targets · 1 analysts

Price is below the lowest target. Median implies +37738%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 8, 2025Aegis Capital
REITERATE
REITERATEBuy
Dec 5, 2024Aegis Capital
REITERATE
REITERATEBuy
Aug 7, 2023Aegis Capital
INITIATE
INITIATEBuy
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 26, 2026 Trading halt
Halt Resumed: SBFM — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-23T23:50:00.000Z | Resumed 2026-10-26T13:00:00.000Z
Oct 14, 2026 SEC
BJI Financial Group has filed a Schedule 13G disclosing a 6.0% passive stake in Sunshine Biopharma Inc., consisting of…
SC 13G — Impact 3/10
Oct 13, 2026 SEC
CVI Investments, Inc. (managed by Heights Capital Management, Inc.) filed a new SC 13G disclosing a 9.9% passive stake…
SC 13G — Impact 4/10
Oct 9, 2026 SEC
Sunshine Biopharma closed a best-efforts public offering raising approximately $6.0 million in gross proceeds via…
8-K — Impact 6/10
Aug 7, 2026 Insider
NATAN DAVID was granted 58,300 shares
Director
Apr 29, 2026 Event
LANGLARA
Original Approval — INJECTABLE
Apr 14, 2026 Insider
NATAN DAVID was granted 100,000 shares
Director

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 7, 2026
NATAN DAVID
Director
AWARD58,300 sh
Apr 14, 2026
NATAN DAVID
Director
AWARD100,000 sh

Earnings setup

Estimates
Nov 11
reports in 15 days
−$3.40
EPS estimate, this quarter
+15%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$3.40-$3.40–-$3.40+15.0%$9.6M
Next Q-$5.80-$5.80–-$5.80+77.7%$9.8M
Current FY🔒 Fresh data, subscribers only
Next FY-$8.00-$8.00–-$8.00-300.0%$45.0M

Short side

FINRA· Oct 15, 2026
840,899
shares short
+539.6%
vs prior settlement
1.0
days to cover
≈5.5%
of shares outstanding
On the Reg SHO threshold listsince Oct 13, 2026: persistent fails-to-deliver. View list
Trading halts
Oct 23, 2026Resumption ScheduledResumed
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
SBFM Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 26, 2026
Trading halt
Halt Resumed: SBFM — trading resumed after T3 (News and Resumption Times)
Halted 2026-10-23T23:50:00.000Z | Resumed 2026-10-26T13:00:00.000Z
Oct 23, 2026
Trading halt
Trading Halt: SBFM — T3 (News and Resumption Times)
Sunshine Biopharma Inc. Cm | Market: NASDAQ | Code: T3 — News and Resumption Times
Oct 23, 2026
Trading halt
Trading Halt: SBFM — T1 (News Pending)
Sunshine Biopharma Inc. Cm | Market: NASDAQ | Code: T1 — News Pending
Oct 13, 2026
Reg SHO list
Reg SHO Threshold: SBFM entered the threshold list
SUNSHINE BIOPHARMA INC COM PAR | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding
Aug 10, 2026
Earnings date
SBFM Q2 2026 Earnings Scheduled — 2026-08-10

SecBot reports

11 filings · 0 bullish · 6 bearish · 5 neutral
All SBFM filing & press-release reports (11)